Page 1

Crescita Reports Second Quarter 2021 Results and Provides Corporate Update LAVAL , Quebec -- ( BUSINESS WIRE ) -- August 11 , 2021 -- Crescita Therapeutics Inc. ( TSX : CTX and OTC US : CRRTF ) ( “ Crescita " or the " Company " ) , a growth - oriented , innovation driven Canadian commercial dermatology company , today reported its financial results for the second quarter ended June 30 , 2021 ( “ Q2 - F2021 ” ) and provided a corporate update . All amounts presented are in thousands of Canadian dollars ( “ CAD " ) unless otherwise noted . Financial Highlights Q2 - F2021 vs. Q2 - F2020 ● Revenue was $ 2,949 compared to $ 1,733 , an increase of $ 1,216 ; Gross profit was $ 1,722 compared to $ 1,092 , an increase of $ 630 ; Operating expenses were $ 2,399 compared to $ 2,318 , an increase of $ 81 ; Adjusted EBITDA¹ was $ ( 269 ) compared to $ ( 781 ) , an improvement of $ 512 ; Ending cash position was $ 13,083 compared to $ 9,265 , an increase of $ 3,818 . ¹Please refer to the Non - IFRS Financial Measures section of this press release . Q2 - F2021 and Subsequent Corporate Developments Expansion of Production Volumes within the Manufacturing and Services Segment We received firm purchase orders of approximately $ 7 million within our Manufacturing and Services segment , representing a significant increase in production and sales volume over the next 12 months . The increase in volume is a result of our customers ordering product to support anticipated launches into new key markets and therefore may not be representative of future orders . Launch of Pliaglis in Austria Our licensing partner , Pelpharma Handels GmbH ( “ Pelpharma ” ) , launched Pliaglis in Austria . ● ● - Continued Expansion of Pliaglis® Worldwide - Strong Cash Balance of $ 13.1 Million - Growth in Manufacturing Segment due to New Purchase Orders ● ● Licensing Agreement for Pliaglis with Croma Pharma GmbH We entered into an exclusive commercialization and development license agreement with Croma Pharma GmbH ( “ Croma ” ) , a globally acclaimed pharmaceutical company with specializations in medical aesthetics , ophthalmology , and orthopaedics , for the rights to Pliaglis in nine countries comprising : Germany , the United Kingdom , Ireland ,